Listing of Claims:

Claim 1 (previously presented) A compound of the formula



(I)

in racemic, enantiomeric or diastereoisomeric form and all combinations of these forms, wherein

R^1 is selected from the group consisting of hydrogen, $-OR^3$, $-SR^3$, oxo and cyclic acetal,

R^3 is selected from the group consisting of hydrogen, alkyl, arylalkyl, heterocycloalkylcarbonyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl,

the alkyl, aryl or heterocycloalkyl are unsubstituted or substituted by at least one member selected from the group consisting of alkyl, -OH, alkoxy, nitro, cyano, halogen and $-NR^4R^5$;

R^4 and R^5 are independently selected from the group consisting of hydrogen or alkyl, or R^4 and R^5 together with the nitrogen atom to which they are attached form an optionally substituted heterocycle,

R^2 is selected from the group consisting of hydrogen, alkyl, aryl and aralkyl, the aryl group being unsubstituted or substituted by at least one member selected from the group consisting of $-OR^6$, $-NR^7R^8$, halogen, cyano, nitro and alkyl,

R^6, R^7 and R^8 are independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl,

A is



A4

in which R^{38} is selected from the group consisting of hydrogen, alkyl, $-(CH_2)_q-NR^{39}R^{40}$ and aralkyl, the aryl being unsubstituted or substituted by at least one member selected from the group consisting of -OH, alkyl, halogen, nitro, alkoxy and $-NR^{39}R^{40}$,

q is an integer between 2 and 6;

R^{39} and R^{40} are independently selected from the group consisting of hydrogen, alkyl and $-COR^{41}$, or R^{39} and R^{40} together with the nitrogen atom form an optionally substituted heterocycle,

R^{41} is selected from the group consisting of hydrogen, alkyl, alkoxy and $-NR^{42}R^{43}$,

R^{42} and R^{43} are independently selected from the group consisting of hydrogen or alkyl, or R^{42} and R^{43} together with the nitrogen atom to which they are attached form an optionally substituted heterocycle,

T is $-(CH_2)_m-$ with m = 1 or 2,

X is selected from the group consisting of $-(CH_2)_n-$, $-(CH_2)_n-CO-$, $-N(R^{45})-CO-(CH_2)_n-CO-$, $-N(R^{45})-CO-D-CO-$, $-CO-N(R^{45})-D-CO-$, $-CO-D-CO-$, $-CH=CH-(CH_2)_n-CO-$, $-N(R^{45})-(CH_2)_n-CO-$, $-N(R^{45})-CO-C(R^{46}R^{47})-CO-$, $-O-(CH_2)_n-CO-$, $-N(R^{45})-CO-NH-C(R^{46}R^{47})-CO-$, $-CO-N(R^{45})-C(R^{46}R^{47})-CO-$, $-S-(CH_2)_n-CO-$ and -Z-CO-;

D is phenylene unsubstituted or substituted by at least one member selected from the group consisting of alkyl, alkoxy, -OH, nitro, halogen, cyano, and carboxyl optionally esterified by alkyl;

Z is a heterocycle,

R^{45} is hydrogen or alkyl,

R^{46} and R^{47} are independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl, the alkyl and aryl groups are unsubstituted or substituted by at least one member selected from the group consisting of -OH, -SH, halogen, nitro, alkyl, alkoxy, alkylthio, aralkoxy, aryl-alkylthio, $-NR^{48}R^{49}$ and carboxyl optionally esterified by alkyl;

R^{48} and R^{49} are independently selected from the group consisting of hydrogen, alkyl and $-COR^{50}$, or R^{48} and R^{49} together with the nitrogen atom to which they are attached form an optionally substituted heterocycle;

R^{50} is selected from the group consisting of hydrogen, alkyl, alkoxy and $-NR^{51}R^{52}$,

R^{51} and R^{52} are independently hydrogen or alkyl, or R^{51} and R^{52} together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

n is an integer between 0 and 6;

Y is $-(CH_2)_p-$;

R^{57} is hydrogen, alkyl, alkoxy and $-NR^{56}R^{59}$,

R^{58} and R^{59} are independently selected from the group consisting of hydrogen or alkyl, or R^{58} and R^{59} together with the nitrogen atom to which they are attached form an optionally substituted heterocycle;

p is an integer between 0 and 6;

Het is a heterocycle, and a pharmaceutically acceptable addition salt with acids or bases thereof,

with the exception of the compounds of formula (I) wherein Het is tetrahydrofuran or tetrahydropyran, R^1 is OR^3, R^3 is selected from the group consisting of hydrogen, alkyl, arylalkyl, heterocycloalkylcarbonyl, the heterocycloalkyl being connected by a carbon atom, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl, R^2 is hydrogen and Y is $-(CH_2)_p-$ with p=0, the X is $-CO-N(R^{45})-C(R^{46}R^{47})-CO-$ with $R^{45} = R^{46} = H$.

Claim 2 (previously presented) A compound of claim 1, wherein Het is a monocyclic of 1 to 2 heteroatoms selected from the group consisting of O and N.

Claim 3 (previously presented) A compound of claim 1 wherein Het is selected from the group consisting of tetrahydrofuran, dioxolane, pyrrolidine and 1,3-oxazolidine, and R^1 is selected from the group consisting of hydrogen, $-OR^3$ and oxo.

Claim 4 (previously presented) A compound of claim 1 wherein X is selected from the group consisting of $-(CH_2)_n-$, $-(CH_2)_n-CO-$, $-O-(CH_2)_n-CO-$, $-CO-N(R^{45})-D-CO-$, $-N(R^{45})-CO-(CH_2)_n-CO-$, $-N(R^{45})-CO-C(R^{46}R^{47})-CO-$, $-N(R^{45})-CO-NH-C(R^{46}R^{47})-CO-$, $-N(R^{45})-(CH_2)_n-CO-$, $-CO-N(R^{45})-C(R^{46}R^{47})-CO$ and -Z-CO-.

Claim 5 (previously presented) A compound of claim 4, wherein R^{45} and R^{47} are hydrogen, R^{46} is selected from the group consisting of hydrogen, alkyl or phenyl, D phenylene and Z is thiazole.

Claim 6 (previously presented) A compound of claim 1 wherein R^2 is hydrogen or aralkyl.

Claim 7 (previously presented) A compound of claim 1 wherein A is either A1 with W being sulfur; or A'1; or A2 with R^{24}, R^{25} and R^{26} being independently hydrogen or alkyl and Q is $-OR^{33}$; or A3 with T being $-(CH_2)_2-$; or A4 with T being $-(CH_2)-$.

Claim 8 (previously presented) A compound of claim 1 wherein A is selected from the group consisting of











and

Claims 9-10 (cancelled)

Claim 11 (previously presented) A pharmaceutical composition for inhibition of calpains and/or reactive oxygen species comprising a calpain inhibiting or reactive oxygen species amount of a compound of claim 1 and a pharmaceutical carrier.

Claim 12 (currently amended) A method of inhibiting calpain and/or reactive oxygen species in warm-blooded animals comprising administering to warm-blooded animals in need thereof a calpain inhibiting amount and/or reactive oxygen species inhibiting amount of a compound of the formula



(I_a)

in racemic, enantiomeric, diastereoisomeric form or all combinations of these forms,

wherein R_a^1 is selected from the group consisting of hydrogen, $-OR^3$, $-SR^3$, oxo and cyclic acetal,

R^3 is selected from the group consisting of hydrogen, alkyl, arylalkyl, heterocycloalkylcarbonyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl,

in which the alkyl, aryl or heterocycloalkyl are unsubstituted or substituted by at least one member selected from the group consisting of alkyl, -OH, alkoxy, nitro, cyano, halogen and $-NR^4R^5$;

R^4 and R^5 are, independently, hydrogen or alkyl, or R^4 and R^5 together with the nitrogen atom to which they are attached form an optionally substituted heterocycle,

R_a^2 is selected from the group consisting of hydrogen, alkyl, aryl and aralkyl, the aryl being unsubstituted or substituted by at least one member selected from the group consisting of $-OR^6$, $-NR^7R^8$, halogen, cyano, nitro and alkyl,

R^6, R^7 and R^8 are independently, hydrogen, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl;

A is



A4

wherein R^{38} is selected from the group consisting of hydrogen, alkyl, $-(CH_2)_q-NR^{39}R^{40}$ and aralkyl, the aryl is unsubstituted or substituted by at least one member selected from the group consisting of -OH, alkyl, halogen, nitro, alkoxy and $-NR^{39}R^{40}$,

q is an integer between 2 and 6;

or

R^{39} and R^{40} are independently selected from the group consisting of hydrogen, alkyl and $-COR^{41}$, or R^{39} and R^{40} together with the nitrogen atom form an optionally substituted heterocycle,

R^{41} is selected from the group consisting of hydrogen, alkyl, alkoxy and $-NR^{42}R^{43}$,

R^{42} and R^{43} are independently selected from the group consisting of hydrogen or alkyl, or R^{42} and R^{43} together with the nitrogen atom to which they are attached form an optionally substituted heterocycle,

T is $-(CH_2)_m-$ with m = 1 or 2,

X_a is selected from the group consisting of $-(CH_2)_n-$, $-(CH_2)_n-CO-$, $-N(R^{45})-CO-(CH_2)_n-CO-$, $-N(R^{45})-CO-D-CO-$, $-CO-N(R^{45})-D-CO-$, $-CO-D-CO-$, $-CH=CH-(CH_2)_n-CO-$, $-N(R^{45})-(CH_2)_n-CO-$, $-N(R^{45})-CO-C(R^{46}R^{47})-CO-$, $-O-(CH_2)_n-CO-$, $-N(R^{45})-CO-NH-C(R^{46}R^{47})-CO-$, $-CO-N(R^{45})-C(R^{46}R^{47})-CO-$, $-S-(CH_2)_n-CO-$ and -Z-CO-;

D is phenylene unsubstituted or substituted by at least one member selected from the group consisting of alkyl, alkoxy, -OH, nitro, halogen, cyano and carboxyl optionally esterified by an alkyl;

Z is a heterocycle,

R^{45} is hydrogen or alkyl;

R^{46} and R^{47} are independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl, the alkyl and aryl groups are substituted by one member of the group consisting of -OH, -SH, halogen, nitro, alkyl, alkoxy, alkylthio, aralkoxy, aryl-alkylthio, $-NR^{48}R^{49}$ and carboxyl optionally esterified by alkyl;

R^{48} and R^{49} are independently selected from the group consisting of hydrogen, alkyl and $-COR^{50}$, or R^{48} and R^{49} together with the nitrogen atom to which they are attached form an optionally substituted heterocycle,

R^{50} is selected from the group consisting of hydrogen, alkyl, alkoxy and $-NR^{51}R^{52}$,

R^{51} and R^{52} are independently selected from the group consisting of hydrogen or alkyl, or R^{51} and R^{52} together with the nitrogen atom to which they are attached form an optionally substituted heterocycle;

n is an integer between 0 and 6;

Y_a is $-(CH_2)_p-[,];$

p is an integer from 0 to 6;

Het_a is a heterocycle,

and pharmaceutically acceptable addition salts thereof with acids or bases.

Claims 13-15 (cancelled)

Claim 16 (previously presented) The method of claim 12 wherein Het is a monocyclic containing 1 to 2 heteroatoms of O or N.

Claim 17 (previously presented) The method of claim 12 wherein Het is selected from the group consisting of tetrahydrofuran, dioxolane pyrrolidine, and 1,3-oxazolidine, and R^1 is selected from the group consisting of hydrogen, $-OR^3$ and oxo.

Claim 18 (previously presented) The method of claim 12 wherein X is selected from the group consisting of $-(CH_2)_n-$, $-(CH_2)_n-CO-$, $-O-(CH_2)_n-CO-$, $-CO-N(R^{45})-D-CO-$, $-N(R^{45})-CO-(CH_2)_n-CO-$, $-N(R^{45})-CO-C(R^{46}R^{47})-CO-$, $-N(R^{45})-CO-NH-C(R^{46}R^{47})-CO-$, $-N(R^{45})-(CH_2)_n-CO-$, $-CO-N(R^{45})-C(R^{46}R^{47})-CO$ and -Z-CO-.

Claim 19 (previously presented) The method of claim 12 wherein R^{45} and R^{47} are hydrogen, R^{46} is hydrogen, alkyl and phenyl, D is phenylene and Z is thiazole.

Claim 20 (previously presented) The method of claim 12 wherein R^2 is hydrogen or aralkyl.

Claims 21-24 (cancelled)

Claim 25 (new) A compound of claim 1 wherein A is A4 and T is $-(CH_2)-$

Claim 26 (new) A compound selected from the group consisting of

N^1-[(3S)-2-hydroxytetrahydro-3-furanyl]-2-phenyl-N^3-(1-propyl-2,3-dihydro-1H-indol-5-yl)malonamide;

N^1-[(3S)-2-hydroxytetrahydro-3-furanyl]-N^2-(1-propyl-2,3-dihydro-1H-indol-5-yl)ethanediamide;

N-[(3S)-2-hydroxytetrahydro-3-furanyl]-5-indolinecarboxamide;

(2S)-2-({[(1-benzyl-2,3-dihydro-1H-indol-5-yl)amino]carbonyl}amino)-N-[(3S)-2-hydroxytetrahydro-3-furanyl]-4-methylpentanamide;

(2S)-N-[(3S)-2-hydroxytetrahydro-3-furanyl]-4-methyl-2-[({[1-(1-naphthylmethyl)-2,3-dihydro-1H-indol-5-yl]amino}carbonyl)amino]pentanamide;

in racemic, enantiomeric or diastereoisomeric form and all combinations of these forms; or a pharmaceutically acceptable addition salt with acids or bases thereof.

Claim 27 (new) The method of claim 12 wherein A is A4 and T is $-(CH_2)-$.

Claim 28 (new) The method of claim 12 wherein the compound is selected from the group consisting of

N^1-[(3S)-2-hydroxytetrahydro-3-furanyl]-2-phenyl-N^3-(1-propyl-2,3-dihydro-1H-indol-5-yl)malonamide;

N^1-[(3S)-2-hydroxytetrahydro-3-furanyl]-N^2-(1-propyl-2,3-dihydro-1H-indol-5-yl)ethanediamide;

N-[(3S)-2-hydroxytetrahydro-3-furanyl]-5-indolinecarboxamide;

(2S)-2-({[(1-benzyl-2,3-dihydro-1H-indol-5-yl)amino]carbonyl}amino)-N-[(3S)-2-hydroxytetrahydro-3-furanyl]-4-methylpentanamide;

(2S)-N-[(3S)-2-hydroxytetrahydro-3-furanyl]-4-methyl-2-[({[1-(1-naphthylmethyl)-2,3-dihydro-1H-indol-5-yl]amino}carbonyl)amino]pentanamide;

in racemic, enantiomeric or diastereoisomeric form and all combinations of these forms; or a pharmaceutically acceptable addition salt with acids or bases thereof.